Clinical trials: Unresectable Colorectal Liver Metastases
Colorectal Neoplasms, Liver Neoplasms
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
The study was terminated early due to low enrollment with only 2 subjects enrolled and treated after being open for enrollment for over a year. Therefore, no meaningful efficacy analyses could be performed.
- Trial name
- NCT00106054
- Testing
- Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Colorectal Neoplasms
Observational Study for SIR-Spheres Therapy for the Treatment of Unresectable Metastatic Liver Tumors From Primary Colorectal Cancer
This real-world study tries to collect data reflecting routine use of SIR-Spheres in patients diagnosed with unresectable liver metastases from Metastatic Liver Tumors From Primary Colorectal Cancer (mCRC) refractory to or…
- Trial name
- NCT06079242
- Testing
- Resin microspheres containing yttrium-90 (Y-90)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- GrandPharma (China) Co., Ltd.
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
This is a Phase 1/2 study of the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine or pembrolizumab in patients with unresectable, refractory liver metastases of colorectal…
- Trial name
- NCT02842125
- Testing
- Ad-P53, Xeloda, Keytruda
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- MultiVir, Inc.
Colon Cancer Liver Metastasis
Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer
The purpose of this study is to test an experimental anti-cancer immunotherapy called NKR-2 (modified T cells), to treat colorectal cancer with unresectable liver metastases.
- Trial name
- LINK (NCT03370198)
- Testing
- NKR-2 cells
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Celyad Oncology SA
Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
This registry seeks to prospectively gather a large repository of comprehensive observational data reflecting routine use of SIR-Spheres in patients diagnosed with unresectable HCC or unresectable liver metastases from mCRC…
- Trial name
- SIRtain (NCT05967143)
- Testing
- SIRT
- Where
- 9 sites in France, Spain and 1 more
- Volunteers
- 845 people
- Sponsor
- Sirtex Medical
Metastatic Colorectal Cancer, mCRC
LifePearl-Iri Pharmacokinetic Study
The primary purpose of the study is to evaluate the pharmacokinetic profile, safety, and efficacy of LifePearl microspheres loaded with irinotecan in the treatment of liver predominant mCRC by chemoembolization.
- Trial name
- NCT02547480
- Testing
- TACE with irinotecan loaded LifePearl
- Where
- 3 sites in Belgium, Germany
- Volunteers
- 15 people
- Sponsor
- Terumo Europe N.V.
Colorectal Cancer
A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
This open-label, single arm, multicenter study evaluated the resection rate in participants with colorectal cancer and previously untreated unresectable liver-only metastases after adding bevacizumab to 5-FU based doublet…
- Trial name
- NCT01695772
- Testing
- 5-FU based doublet chemotherapy, bevacizumab
- Where
- 7 sites in China
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer Metastatic
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
This study is a randomized, multi-center study that will compare the efficacy and safety of selective internal radiation therapy (SIRT) using SIR-Spheres microspheres plus a standard chemotherapy regimen of FOLFOX6m versus…
- Trial name
- FOXFIREGlobal (NCT01721954)
- Testing
- FOLFOX6m, SIR-Spheres microspheres
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 209 people
- Sponsor
- Sirtex Medical
Liver Neoplasms
TheraSphere Japan Pre-Market Study
To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.
- Trial name
- INDIGO (NCT07377487)
- Testing
- TheraSphere Y-90 glass microsphere
- Where
- 5 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Boston Scientific Corporation
Colorectal Neoplasms
Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer
This study will include two parts: Phase I part is a dose-escalation study to assess the safety of increasing doses of TG6002 in combination with oral flucytosine (5-FC) in consecutive cohorts of 3 to 6 patients with colorectal…
- Trial name
- NCT04194034
- Testing
- TG6002, Flucytosine (5-FC)
- Where
- 3 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Transgene
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Melanoma, Carcinoma, Hepatocellular
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2…
- Conditions
- Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
- Trial name
- NCT05091346
- Testing
- E7386, Pembrolizumab, Lenvatinib
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 89 people
- Sponsor
- Eisai Inc.
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
This single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin and capecitabine (XELOX) in patients with…
- Trial name
- NCT00700570
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin
- Where
- 6 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Colorectal Adenocarcinoma
Safety and Feasibility of Electrochemotherapy in Unresectable Colorectal Adenocarninoma Liver Metastases
Electrochemotherapy (ECT) is a non-thermal tumour ablation modality. It consists of the local potentiation, by means of local reversible electroporation of tumour tissues, of the antitumor activity of non-permeant or poorly…
- Trial name
- NCT02709811
- Testing
- Electrochemotherapy
- Volunteers
- 5 people
- Sponsor
- IGEA
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
This 2 arm study will compare the resection rate of liver metastases and safety of surgery in patients with metastatic colorectal cancer and primarily unresectable liver metastases receiving treatment with Avastin in combination…
- Trial name
- NCT00778102
- Testing
- 5-FU, Irinotecan, Leucovorin
- Where
- 19 sites in Austria, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche